Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
or
Privacy Policy | Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
or
Privacy Policy | Disclaimer
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation
Healthcare
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
No Data Exists for symbol: BFRI
{data.pricedata.last | asQHLast tLang} {data.pricedata.last | asQHLast tLang | asCurrency data.key.currency tLang} {data.pricedata.change | asQHLast tLang } | {data.pricedata.changepercent | numeraljs '0.00' | postFix '%' tLang} {data.status.regsho} {data.status.halt.code} {tplLang.bid| toLang tLang}: {data.pricedata.bid | asQHLast tLang} x {data.pricedata.bidsize} {tplLang.ask| toLang tLang}: {data.pricedata.ask | asQHLast tLang} x {data.pricedata.asksize} Volume: {data.pricedata.sharevolume | numeraljs '0,0' 'N/A' tLang} Volume: {data.pricedata.sharevolume | numeraljs '0,0' '0' tLang}
{tplLang.low| toLang tLang}: {data.pricedata.low | asQHLast tLang} | {tplLang.high| toLang tLang}: {data.pricedata.high | asQHLast tLang} | {tplLang.yearlow|toLang tLang}: {data.fundamental.week52low.content | asQHLast tLang} | {tplLang.yearhigh|toLang tLang}: {data.fundamental.week52high.content | asQHLast tLang}
{tplLang.afterhours| toLang tLang} {data.afterhours.change | asQHLast tLang } | {data.tz | asTimezone tLang} Volume: {data.afterhours.sharevolume | numeraljs '0,0' 'N/A' tLang}
{data.tz | asTimezone tLang}
NDAQ:BFRI - Post by User
Biofrontera Inc
Bullboard Posts
Next >>
Post by PressReleaseon Nov 10, 2022 11:53am
349 Views
Post# 35088684
New Press Release - Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of...read article.
Comment on this Post
Bullboard Posts
Next >>Capitalizing on the Bitcoin Lightning Network: LQWD Technologies
Telesat secures $2.54B government funding for Lightspeed satellites
U.S. courts overturn jury verdict in BMO Ponzi scheme lawsuit
How an undervalued lithium stock is making strides in Ontario
Gold’s new high: Your access to buying the precious metal in this rush
Thank You
Your Report has been submitted.
Report Abusive Content
Sign up to get access
You are already a member! Please enter your password to sign in.
Forgot password?
Back
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
{{reasonError}}
{{feedbackError}}
{{submitMsg}}
Interested in these industries and sectors?
Receive investor kits and email updates from Stockhouse and directly from these companies.
Healthcare
All None
Consumer Cyclical
All None
Metals & Mining
All None
Energy
All None
Communication Services
All None
Utilities
All None
You are already a member! Please enter your password to sign in.
Forgot password?
Back
I consent to receiving investment related electronic messages from Stockhouse and the companies selected. I may withdraw my consent at any time.
